2clx: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
[[Image:2clx.gif|left|200px]]
[[Image:2clx.gif|left|200px]]


{{Structure
<!--
|PDB= 2clx |SIZE=350|CAPTION= <scene name='initialview01'>2clx</scene>, resolution 1.80&Aring;
The line below this paragraph, containing "STRUCTURE_2clx", creates the "Structure Box" on the page.
|SITE= <scene name='pdbsite=AC1:F18+Binding+Site+For+Chain+A'>AC1</scene>
You may change the PDB parameter (which sets the PDB file loaded into the applet)
|LIGAND= <scene name='pdbligand=F18:4-[(E)-(3,5-DIAMINO-1H-PYRAZOL-4-YL)DIAZENYL]PHENOL'>F18</scene>
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
|ACTIVITY=  
or leave the SCENE parameter empty for the default display.
|GENE=  
-->
|DOMAIN=
{{STRUCTURE_2clx| PDB=2clx  | SCENE= }}  
|RELATEDENTRY=
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2clx FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2clx OCA], [http://www.ebi.ac.uk/pdbsum/2clx PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2clx RCSB]</span>
}}


'''4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS'''
'''4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS'''
Line 39: Line 36:
[[Category: Slouka, J.]]
[[Category: Slouka, J.]]
[[Category: Strnad, M.]]
[[Category: Strnad, M.]]
[[Category: atp-binding]]
[[Category: Atp-binding]]
[[Category: cdk2]]
[[Category: Cdk2]]
[[Category: cell cycle]]
[[Category: Cell cycle]]
[[Category: cell division]]
[[Category: Cell division]]
[[Category: kinase]]
[[Category: Kinase]]
[[Category: mitosis]]
[[Category: Mitosis]]
[[Category: nucleotide-binding]]
[[Category: Nucleotide-binding]]
[[Category: phosphorylation]]
[[Category: Phosphorylation]]
[[Category: polymorphism]]
[[Category: Polymorphism]]
[[Category: serine-threonine-protein kinase]]
[[Category: Serine-threonine-protein kinase]]
[[Category: serine/threonine- protein kinase]]
[[Category: Serine/threonine- protein kinase]]
[[Category: transferase]]
[[Category: Transferase]]
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 22:27:36 2008''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 02:23:19 2008''

Revision as of 22:27, 3 May 2008

File:2clx.gif

Template:STRUCTURE 2clx

4-ARYLAZO-3,5-DIAMINO-1H-PYRAZOLE CDK INHIBITORS: SAR STUDY, CRYSTAL STRUCTURE IN COMPLEX WITH CDK2, SELECTIVITY, AND CELLULAR EFFECTS


OverviewOverview

In a routine screening of our small-molecule compound collection we recently identified 4-arylazo-3,5-diamino-1H-pyrazoles as a novel group of ATP antagonists with moderate potency against CDK2-cyclin E. A preliminary SAR study based on 35 analogues suggests ways in which the pharmacophore could be further optimized, for example, via substitutions in the 4-aryl ring. Enzyme kinetics studies with the lead compound and X-ray crystallography of an inhibitor-CDK2 complex demonstrated that its mode of inhibition is competitive. Functional kinase assays confirmed the selectivity toward CDKs, with a preference for CDK9-cyclin T1. The most potent inhibitor, 4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol 31b (CAN508), reduced the frequency of S-phase cells of the cancer cell line HT-29 in antiproliferation assays. Further observed cellular effects included decreased phosphorylation of the retinoblastoma protein and the C-terminal domain of RNA polymerase II, inhibition of mRNA synthesis, and induction of the tumor suppressor protein p53, all of which are consistent with inhibition of CDK9.

About this StructureAbout this Structure

2CLX is a Single protein structure of sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects., Krystof V, Cankar P, Frysova I, Slouka J, Kontopidis G, Dzubak P, Hajduch M, Srovnal J, de Azevedo WF Jr, Orsag M, Paprskarova M, Rolcik J, Latr A, Fischer PM, Strnad M, J Med Chem. 2006 Nov 2;49(22):6500-9. PMID:17064068 Page seeded by OCA on Sat May 3 22:27:36 2008

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA